8.01
+0(+0.00%)
Currency In USD
| Previous Close | 8.01 |
| Open | 7.89 |
| Day High | 8.17 |
| Day Low | 7.77 |
| 52-Week High | 9.7 |
| 52-Week Low | 1.03 |
| Volume | 2.5M |
| Average Volume | 2.68M |
| Market Cap | 891.13M |
| PE | -6.07 |
| EPS | -1.32 |
| Moving Average 50 Days | 7.63 |
| Moving Average 200 Days | 4.49 |
| Change | 0 |
If you invested $1000 in Tango Therapeutics, Inc. (TNGX) since IPO date, it would be worth $782.99 as of November 05, 2025 at a share price of $8.01. Whereas If you bought $1000 worth of Tango Therapeutics, Inc. (TNGX) shares 3 years ago, it would be worth $1,032.22 as of November 05, 2025 at a share price of $8.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company
Tango Therapeutics Announces $225 Million Financing
GlobeNewswire Inc.
Oct 23, 2025 11:20 AM GMT
Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital, Nantahala Capital, accounts advised by T. Rowe Pr
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
GlobeNewswire Inc.
Oct 23, 2025 11:00 AM GMT
– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histol